Stock of the Day

Regulus Therapeutics (RGLS)

$1.31

+$0.04 (+3.1%)

Market Cap: $85.81M

About Regulus Therapeutics

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.

The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Recent News

• Regulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying Recently (insidermonkey.com)
• Regulus Therapeutics Inc. (RGLS): Among the Cheapest Stocks Insiders Are Buying Recently (msn.com)